

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 September 2006 (14.09.2006)

PCT

(10) International Publication Number
WO 2006/095166 A1

(51) International Patent Classification:
C07K 14/575 (2006.01) A61K 38/22 (2006.01)

(74) Agents: BRADY, Paul et al.; Abel & Imray, 20 Red Lion Street, London WC1R 4PQ (GB).

(21) International Application Number:
PCT/GB2006/000822

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 9 March 2006 (09.03.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0504857.4 9 March 2005 (09.03.2005) GB

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): IMPE-
RIAL INNOVATIONS LIMITED [GB/GB]; Sherfield
Building, London SW7 2AZ (GB).

(72) Inventors; and



(75) Inventors/Applicants (for US only): MOORE, Stanley [GB/GB]; Bachem UK, Sherdley Business Park, Sullidans Way, St Helens WA9 5GL (GB). GHATEI, Mohammad [GB/GB]; Dept of Metabolic Medicine, Commonwealth Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN (GB). BLOOM, Stephen, Robert [GB/GB]; Dept of Metabolic Medicine, Commonwealth Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN (GB).

Published:

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MODIFIED PYY (3-36) PEPTIDES AND THEIR EFFECTS ON FEEDING BEHAVIOUR



(57) Abstract: The present invention relates to compounds of formula (I); variants or derivatives thereof, or salts or solvates thereof. The present invention also relates to the use of such compounds to control appetite, feeding, food intake, energy expenditure and calorie intake, particularly in the treatment of obesity.

-1-

MODIFIED PYY(3-36) PEPTIDES AND THEIR EFFECTS ON FEEDING BEHAVIOR

1. FIELD OF THE INVENTION

5 This application relates to the use of agents to control appetite, feeding, food intake, energy expenditure and calorie intake, particularly in the field of obesity.

2. BACKGROUND OF THE INVENTION

10 According to the National Health and Nutrition Examination Survey (NHANES III, 1988 to 1994), between one third and one half of men and women in the United States are overweight. In the United States, sixty percent of men and fifty-one percent of women, of the age of 20 or older, are either overweight or obese. In addition, a large percentage of children in the United States are overweight or obese.

15 The cause of obesity is complex and multi-factorial. Increasing evidence suggests that obesity is not a simple problem of self-control but is a complex disorder involving appetite regulation and energy metabolism. In addition, obesity is associated with a variety of conditions associated with increased morbidity and mortality in a population. Although the etiology of obesity is not definitively established, genetic, metabolic, biochemical, 20 cultural and psychosocial factors are believed to contribute. In general, obesity has been described as a condition in which excess body fat puts an individual at a health risk.

There is strong evidence that obesity is associated with increased morbidity and mortality. Disease risk, such as cardiovascular disease risk and type 2 diabetes disease risk, increases 25 independently with increased body mass index (BMI). Indeed, this risk has been quantified as a five percent increase in the risk of cardiac disease for females, and a seven percent increase in the risk of cardiac disease for males, for each point of a BMI greater than 24.9 (see Kenchaiah et al., *N. Engl. J. Med.* 347:305, 2002; Massie, *N. Engl. J. Med.* 347:358, 2002). In addition, there is substantial evidence that weight loss in obese persons 30 reduces important disease risk factors. Even a small weight loss, such as 10% of the initial

-2-

body weight in both overweight and obese adults has been associated with a decrease in risk factors such as hypertension, hyperlipidemia, and hyperglycemia.


Although diet and exercise provide a simple process to decrease weight gain, overweight
5 and obese individuals often cannot sufficiently control these factors to effectively lose weight. Pharmacotherapy is available; several weight loss drugs have been approved by the Food and Drug Administration that can be used as part of a comprehensive weight loss program. However, many of these drugs have serious adverse side effects. When less
10 invasive methods have failed, and the patient is at high risk for obesity related morbidity or mortality, weight loss surgery is an option in carefully selected patients with clinically severe obesity. However, these treatments are high-risk, and suitable for use in only a limited number of patients. It is not only obese subjects who wish to lose weight. People with weight within the recommended range, for example, in the upper part of the recommended range, may wish to reduce their weight, to bring it closer to the ideal weight.
15 Thus, a need remains for agents that can be used to effect weight loss in overweight and obese subjects.

In WO03/026591, it is disclosed that peripheral administration of peptide YY (hereinafter PYY), or an agonist thereof, to a subject results in decreased food intake, caloric intake,
20 and appetite, and an alteration in energy metabolism. It is disclosed that the PYY or agonist thereof is preferably an N-terminally deleted PYY molecule PYY₃₋₃₆.

3. SUMMARY OF THE INVENTION

The present invention provides a compound of formula (I):

25



(I)

a variant or derivative thereof;

-3-

or a salt or solvate thereof.

The invention also provides uses of a compound of formula (I), methods that use a compound of formula (I), compositions comprising a compound of formula (I), and
5 methods of making a compound of formula (I).

4. BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the results of experiments in which the appetite suppressing effects in mice of a compound of the invention were compared with native PYY(3-36), saline, allo-
10 Ile PYY(3-36) or D-IlePYY(3-36).

Figures 2A and 2B show the results of experiments in which the appetite suppressing effects in mice of 30 and 100 µg/kg of a compound of the invention were compared with the same two quantities of native PYY(3-36) and saline.

Figures 3A and 3B show the results of experiments in which the appetite suppressing effects in rats of 30 and 100 µg/kg of a compound of the invention were compared with the
15 same two quantities of native PYY(3-36) and saline.

5. SEQUENCE LISTING

The amino acid sequences listed in the application are shown using standard letter
20 abbreviations for amino acids.

6. DEFINITIONS

In order to facilitate review of the various embodiments of this disclosure, the following explanations of specific terms are provided:

25

Animal: Living multi-cellular vertebrate organisms, a category that includes, for example, mammals and birds. The term mammal includes both human and non-human mammals. Similarly, the term "subject" includes both human and veterinary subjects.

-4-

Appetite: A natural desire, or longing for food. In one embodiment, appetite is measured by a survey to assess the desire for food. Increased appetite generally leads to increased feeding behavior.

- 5 **Appetite Suppressants:** Compounds that decrease the desire for food. Commercially available appetite suppressants include, but are not limited to, amfepramone (diethylpropion), phentermine, mazindol and phenylpropanolamine fenfluramine, dexfenfluramine, and fluoxetine.
- 10 **Body Mass Index (BMI):** A mathematical formula for measuring body mass, also sometimes called Quetelet's Index. BMI is calculated by dividing weight (in kg) by height² (in meters²). The current standards for both men and women accepted as "normal" are a BMI of 20-24.9 kg/m². In one embodiment, a BMI of greater than 25 kg/m² can be used to identify an obese subject. Grade I obesity corresponds to a BMI of 25-29.9 kg/m².
- 15 Grade II obesity corresponds to a BMI of 30-40 kg/m²; and Grade III obesity corresponds to a BMI greater than 40 kg/m² (Jequier, *Am. J Clin. Nutr.* 45:1035-47, 1987). Ideal body weight will vary among species and individuals based on height, body build, bone structure, and sex.
- 20 **Conservative substitutions:** The replacement of an amino acid residue by another, biologically similar residue in a polypeptide. The term "conservative variation" also includes the use of a substituted amino acid, i.e. an amino with one or more atoms replaced with another atom or group, in place of a parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.
- 25 **Diabetes:** A failure of cells to transport endogenous glucose across their membranes either because of an endogenous deficiency of insulin and/or a defect in insulin sensitivity. Diabetes is a chronic syndrome of impaired carbohydrate, protein, and fat metabolism owing to insufficient secretion of insulin or to target tissue insulin resistance. It occurs in
- 30 two major forms: insulin-dependent diabetes mellitus (IDDM, type I) and non-insulin dependent diabetes mellitus (NIDDM, type II) which differ in etiology, pathology, genetics, age of onset, and treatment.

-5-

The two major forms of diabetes are both characterized by an inability to deliver insulin in an amount and with the precise timing that is needed for control of glucose homeostasis. Diabetes type I, or insulin dependent diabetes mellitus (IDDM) is caused by the destruction of β cells, which results in insufficient levels of endogenous insulin. Diabetes
5 type II, or non-insulin dependent diabetes, results from a defect in both the body's sensitivity to insulin, and a relative deficiency in insulin production.

Food intake: The amount of food consumed by an individual. Food intake can be measured by volume or by weight. For example, food intake may be the total amount of
10 food consumed by an individual. Or, food intake may be the amount of proteins, fat, carbohydrates, cholesterol, vitamins, minerals, or any other food component, of the individual. "Protein intake" refers to the amount of protein consumed by an individual. Similarly, "fat intake," "carbohydrate intake," "cholesterol intake," "vitamin intake," and "mineral intake" refer to the amount of proteins, fat, carbohydrates, cholesterol, vitamins,
15 or minerals consumed by an individual.

Hyperpolarization: A decrease in the membrane potential of a cell. Inhibitory neurotransmitters inhibit the transmission of nerve impulses via hyperpolarization. This hyperpolarization is called an inhibitory postsynaptic potential (IPSP). Although the
20 threshold voltage of the cell is unchanged, a hyperpolarized cell requires a stronger excitatory stimulus to reach threshold.

Normal Daily Diet: The average food intake for an individual of a given species. A normal daily diet can be expressed in terms of caloric intake, protein intake, carbohydrate
25 intake, and/or fat intake. A normal daily diet in humans generally comprises the following: about 2,000, about 2,400, or about 2,800 to significantly more calories. In addition, a normal daily diet in humans generally includes about 12 g to about 45 g of protein, about 120 g to about 610 g of carbohydrate, and about 11 g to about 90 g of fat. A low calorie diet would be no more than about 85%, and preferably no more than about
30 70%, of the normal caloric intake of a human individual.

-6-

In animals, the caloric and nutrient requirements vary depending on the species and size of the animal. For example, in cats, the total caloric intake per pound, as well as the percent distribution of protein, carbohydrate and fat varies with the age of the cat and the reproductive state. A general guideline for cats, however, is 40 cal/lb/day (18.2 cal/kg/day). About 30% to about 40% should be protein, about 7% to about 10% should be from carbohydrate, and about 50% to about 62.5% should be derived from fat intake. One of skill in the art can readily identify the normal daily diet of an individual of any species.

10 **Obesity:** A condition in which excess body fat may put a person at health risk (see Barlow and Dietz, *Pediatrics* 102:E29, 1998; National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI), *Obes. Res.* 6 (suppl. 2):51S-209S, 1998). Excess body fat is a result of an imbalance of energy intake and energy expenditure. For example, the Body Mass Index (BMI) may be used to assess obesity. In one commonly used
15 convention, a BMI of 25.0 kg/m² to 29.9 kg/m² is overweight, while a BMI of 30 kg/m² is obese.

In another convention, waist circumference is used to assess obesity. In this convention, in men a waist circumference of 102 cm or more is considered obese, while in women a waist
20 circumference of 89 cm or more is considered obese. Strong evidence shows that obesity affects both the morbidity and mortality of individuals. For example, an obese individual is at increased risk for heart disease, non-insulin dependent (type 2) diabetes, hypertension, stroke, cancer (e.g. endometrial, breast, prostate, and colon cancer), dyslipidemia, gall bladder disease, sleep apnea, reduced fertility, and osteoarthritis, amongst others (see
25 Lyznicki et al., *Am. Fam. Phys.* 63:2185, 2001).

Overweight: An individual who weighs more than their ideal body weight. An overweight individual can be obese, but is not necessarily obese. For example, an overweight individual is any individual who desires to decrease their weight. In one
30 convention, an overweight individual is an individual with a BMI of 25.0 kg/m² to 29.9 kg/m²

-7-

Pegylated and pegylation: the process of reacting a poly(alkylene glycol), preferably an activated poly(alkylene glycol) to form a covalent bond. A facilitator may be used, for example an amino acid, e.g. lysine. Although "pegylation" is often carried out using poly(ethylene glycol) or derivatives thereof, such as methoxy poly(ethylene glycol), the
5 term is not limited herein to the use of methoxy poly(ethylene glycol) but also includes the use of any other useful poly(alkylene glycol), for example poly(propylene glycol).

Peptide YY (PYY): The term PYY as used herein refers to a peptide YY polypeptide, a hormone secreted into the blood by cells lining the lower small intestine (the ileum) and
10 the colon.

Peripheral Administration: Administration outside of the central nervous system. Peripheral administration does not include direct administration to the brain. Peripheral administration includes, but is not limited to intravascular, intramuscular, subcutaneous,
15 inhalation, oral, rectal, transdermal or intra-nasal administration

Polypeptide: A polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha-amino acids, either the L-optical isomer or the D-optical isomer can be used, the L-isomers being preferred. The
20 terms "polypeptide" or "protein" as used herein encompass any amino acid sequence and include modified sequences such as glycoproteins. The term "polypeptide" specifically covers naturally occurring proteins, as well as those which are recombinantly or synthetically produced. The term "polypeptide fragment" refers to a portion of a polypeptide, for example a fragment which exhibits at least one useful sequence in binding
25 a receptor. The term "functional fragments of a polypeptide" refers to all fragments of a polypeptide that retain an activity of the polypeptide. Biologically functional peptides can also include fusion proteins, in which the peptide of interest has been fused to another peptide that does not decrease its desired activity.


Therapeutically effective amount: A dose sufficient to prevent advancement, or to cause regression of a disorder, or which is capable of relieving a sign or symptom of a disorder, or which is capable of achieving a desired result. In several embodiments, a
30

-8-

therapeutically effective amount of a compound of the invention is an amount sufficient to inhibit or halt weight gain, or an amount sufficient to decrease appetite, or an amount sufficient to reduce caloric intake or food intake or increase energy expenditure.

5 7. DETAILED DESCRIPTION

As mentioned above, the invention provides a compound of formula (I):



(I)

a variant or derivative thereof;
or a salt or solvate thereof.

The compounds of the invention as represented in formula (I) are related to PYY₃₋₃₆ and have D-allo-isoleucine at the position 3 of the PYY derivative molecule. The compounds can thus be named D-allo-Ile³ PYY₃₋₃₆. In native human PYY, isoleucine is located at position 3. It has been found that administration of a particular quantity of D-allo-Ile³ PYY₃₋₃₆ to rats results in a greater decrease in food intake than the same quantity of normal human PYY₃₋₃₆, that is to say PYY₃₋₃₆ with isoleucine at position 3. It has further been found that administration of 30 µg/kg of D-allo-Ile³ PYY₃₋₃₆ to rats or mice results in the same decrease in food intake as 100 µg/kg of native PYY₃₋₃₆.

It has also been found that D-allo-Ile³ PYY₃₋₃₆ has a more sustained effect on food intake reduction. In the mice and rat experiments carried out to date, D-allo-Ile³ PYY₃₋₃₆ was found to decrease food intake over the total period 0-4 hours to a greater extent than native PYY₃₋₃₆. Increased duration of appetite suppression can be particularly important to avoid the effect known as "escape". A short duration appetite suppressant may reduce appetite for the time covered by one meal and, in that meal, the subject typically eats less food. If, however, the appetite suppressant is then metabolized or otherwise removed from the

-9-

circulation of the subject, then by the time of the next mealtime, the subject can regain its “normal” appetite. In view of the subject having eaten a small meal at the previous mealtime, the subject may in fact have an increased appetite by the time of the second meal. If the subject satisfies that appetite, it is possible for the food intake over the two meals, in total, to be no lower than the food intake would have been without the appetite suppressant. That is to say that the subject may have “escaped” from the effects of the appetite suppressant. “Escape” can be reduced by using additional doses of appetite suppressant, or by using an appetite suppressant with a longer duration of action. If the subject has a reduced appetite for longer, then the degree to which it can make up the missed food from one meal in the next meal is reduced as there is a practical limit to the total capacity for food in a particular meal.

Preferably, the PYY₄₋₃₆ is human PYY₄₋₃₆.

The human full length PYY polypeptide is shown in SEQ ID NO: 1; human PYY₄₋₃₆ is shown in SEQ ID NO: 2. The subscripts refer to the location on the full length PYY molecule in the species in question, beginning at the N-terminus. Thus PYY₄₋₃₆ is a peptide PYY molecule lacking amino acids 1 to 3 at the N-terminus. Analogous numbering is used for other fragments and variants of PYY described herein.

The PYY₄₋₃₆ in a molecule of the invention may be, or may be related to, a PYY from a species other than human. The sequence of PYYs of various species are included in Table 1 (SEQ ID NOS: 3 to 10), including e.g. rat and pig PYY. The PYY₄₋₃₆ in a molecule of the invention may also be taken from any of those sequences.

Table 1: PYY sequence of various species

PEPTIDE YY	AA SEQUENCE
Human	YPIKPEAPGEDASPEELNRYYA\$LRHYLNLVTRQRY (SEQ ID NO: 1)
Human 4-36	KPEAPGEDASPEELNRYYA\$LRHYLNLVTRQRY (SEQ ID NO: 2)
Rat	YPAKPEAPGEDASPEELSRYYA\$LRHYLNLVTRQRY (SEQ ID NO: 3)
Pig	YPAKPEAPGEDASPEELSRYYA\$LRHYLNLVTRQRY (SEQ ID NO: 4)

-10-

Guinea pig	YPSKPEAPGSDASPEELARYYASLRHYLNLVTRQRY (SEQ ID NO: 5)
Frog	YPPKPENPGEDASPEEMTKYLTALRHYINLVTRQRY (SEQ ID NO: 6)
Raja	YPPKPENPGDDAAPEELAKYYSALRHYINLITRQRY (SEQ ID NO: 7)
Dogfish	YPPKPENPGEDAPPEELAKYYSALRHYINLITRQRY (SEQ ID NO: 8)
5 Lampetra	FPPKPDNPGDNASPEQMARYKAAVRHYINLITRQRY (SEQ ID NO: 9)
Petromyzon	MPPKPDNPSDASPEELSKYMLAVRNYINLITRQRY (SEQ ID NO: 10)

In a similar manner to PYY₃₋₃₆, the compounds of the invention are typically selective for the Y2 receptor. That is, they bind with higher affinity to Y2 compared to other receptors, such as Y1, Y3, Y4, Y5 and Y6. These receptors are recognized based on binding affinities, pharmacology, and sequence (if known). Most, if not all of these receptors are G protein coupled receptors. The Y1 receptor is generally considered to be postsynaptic and mediates many of the known actions of neuropeptide Y in the periphery. Originally, this receptor was described as having poor affinity for C-terminal fragments of neuropeptide Y, such as the 13-36 fragment, but interacts with the full length neuropeptide Y and peptide YY with equal affinity (e.g., see PCT publication WO 93/09227).

Pharmacologically, the Y2 receptor is distinguished from Y1 by exhibiting affinity for C-terminal fragments of neuropeptide Y. The Y2 receptor is most often differentiated by the affinity of neuropeptide Y(13-36), although the 3-36 fragment of neuropeptide Y and peptide YY provides improved affinity and selectivity (see Dumont et al., *Society for Neuroscience Abstracts* 19:726, 1993). Signal transmission through both the Y1 and the Y2 receptors are coupled to the inhibition of adenylate cyclase. Binding to the Y2 receptor was also found to reduce the intracellular levels of calcium in the synapse by selective inhibition of N-type calcium channels. In addition, the Y2 receptor, like the Y1 receptors, exhibits differential coupling to second messengers (see U.S. Patent No. 6,355,478). Y2 receptors are found in a variety of brain regions, including the hippocampus, substantia nigra-lateralis, thalamus, hypothalamus, and brainstem. The human, murine, monkey and rat Y2 receptors have been cloned (e.g., see U.S. Patent No. 6,420,352 and U.S. Patent No. 6,355,478).

10763 WO

-11-

Variants:

The PYY₄₋₃₆ may be a variant of a native PYY₄₋₃₆, for example a variant of native human PYY₄₋₃₆. Variants include PYY₄₋₃₆ molecules with deletions, insertions, inversions, repeats and substitutions, (e.g., conservative substitutions and non-conservative substitutions; see, e.g., Table 2 below) which retain at least some of the activity of a corresponding non-mutated PYY₄₋₃₆ molecule when in a molecule of the invention. More than one amino acid (e.g., 2, 3 or 4) can be deleted or inserted or substituted with another amino acid. Accordingly, the PYY₄₋₃₆ as present in a compound of formula (I) preferably includes at least 29 amino acids of the native PYY₄₋₃₆ sequence. Preferably, the C-terminal six amino acids of native PYY₄₋₃₆ are all present in a molecule of the invention.

Typically conservative substitutions are the replacements, for one another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of Ser and Thr containing hydroxy residues, interchange of the acidic residues Asp and Glu, interchange between the amide residues Asn and Gln, interchange of the basic residues Lys and Arg, interchange of the aromatic residues Phe and Tyr, and interchange of the small-sized amino acids Ala, Ser, Thr, Met and Gly. Guidance concerning how to make phenotypically silent amino acid substitutions, ie substitutions that do not alter the expressed phenotype, is provided in Bowie et al., *Science* 247:1306-1310, 1990.

Table 2: Non-limiting examples of conservative amino acid substitutions

	Original Residue	Conservative Substitutions
25	Ala	Ser
	Arg	Lys
	Asn	Gln, His
	Asp	Glu
	Cys	Ser
30	Gln	Asn
	Glu	Asp
	His	Asn; Gln
	Ile	Leu, Val
	Leu	Ile; Val
35	Lys	Arg; Gln; Glu
	Met	Leu; Ile
	Phe	Met; Leu; Tyr
	Ser	Thr

-12-

Thr
Trp
Tyr
Val

Ser
Tyr
Trp; Phe
Ile; Leu

5

Variants of PYY₄₋₃₆ further include variants in which one or more amino acids (for example 2, 3 or 4) of PYY₄₋₃₆ of one species are substituted by an amino acid present at the equivalent position in PYY derived from a different species. The sequences of PYYs of various species are included in Table 1 above. In particular, variants of human PYY₄₋₃₆ include variants in which one or more amino acids (for example 2, 3 or 4) of human PYY₄₋₃₆ are substituted by an amino acid present at the equivalent position in PYY derived from a different species.

10

Derivatives

A compound of the invention may comprise the structure of formula (I) modified by well known processes including amidation, glycosylation, carbamylation, acylation, for example acetylation, sulfation, phosphorylation, cyclization, lipidization and pegylation. The structure of formula (I) may be modified at random positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

20

A compound of the invention may be a fusion protein, whereby the structure of formula (I) is fused to another protein or polypeptide (the fusion partner) using recombinant methods known in the art. Alternatively, such a fusion protein may be synthetically synthesized by any known method. Such a fusion protein comprises the structure of formula (I). Any suitable peptide or protein can be used as the fusion partner (e.g., serum albumin, carbonic anhydrase, glutathione-S-transferase or thioredoxin, etc.). Preferred fusion partners will not have an adverse biological activity *in vivo*. Such fusion proteins may be made by linking the carboxy-terminus of the fusion partner to the amino-terminus of the structure of formula (I) or vice versa. Optionally, a cleavable linker may be used to link the structure of formula (I) to the fusion partner. A resulting cleavable fusion protein may be cleaved *in vivo* such that an active form of a compound of the invention is released. Examples of such cleavable linkers include, but are not limited to, the linkers D-D-D-D-Y, G-P-R, A-G-

25

30

-13-

G and H-P-F-H-L, which can be cleaved by enterokinase, thrombin, ubiquitin cleaving enzyme and renin, respectively. See, e.g., U.S. Patent No. 6,410,707.

A compound of the invention may be a physiologically functional derivative of the structure of formula (I). The term "physiologically functional derivative" is used herein to denote a chemical derivative of a compound of formula (I) having the same physiological function as the corresponding unmodified compound of formula (I). For example, a physiologically functionally derivative may be convertible in the body to a compound of formula (I). According to the present invention, examples of physiologically functional derivatives include esters, amides, and carbamates; preferably esters and amides.

Pharmaceutically acceptable esters and amides of the compounds of the invention may comprise a C₁₋₆ alkyl-, C₅₋₁₀ aryl-, C₅₋₁₀ ar-C₁₋₆ alkyl-, or amino acid-ester or -amide attached at an appropriate site, for example at an acid group.

Acyl side chains may be advantageous, for example, by their lipophilic nature causing the moiety to bind with albumin, thus causing a greatly reduced rate of clearance from a subject and so increasing half life and duration of effect. Whilst the acyl side chains may be lower acyl, for example C₁- C₉ acyl, especially C₁₋₆ acyl, they are preferred to be C₄₋₄₀, in particular C₈₋₂₅ acyl, especially C₁₆ or C₁₈ acyl. Palmitoyl is especially preferred as an acyl side chain as is lauroyl. Acyl side chains may be added at any position on the peptide back bone. An acyl substituent may be attached to an amino acid residue in such a way that a carboxyl group of the acyl substituent forms an amide bond with an amino group of the amino acid residue. Alternatively, an acyl substituent may be attached to an amino acid residue in such a way that an amino group of the acyl substituent forms an amide bond with a carboxyl group of the amino acid residue. In a further preferred embodiment, the present invention relates to an PYY derivative wherein an acyl substituent is attached to the parent peptide by means of a spacer. For example, the acyl substituent may be attached to the PYY moiety by means of a spacer in such a way that a carboxyl group of the spacer forms an amide bond with an amino group of the PYY moiety. It is especially preferred to add an acyl side chain (optionally via a spacer) at a position in the peptide back bone where a lysine residue is found. This is because lysine, having a four carbon

-14-

atom side chain terminating at an epsilon-amino group, is particularly suitable for easily adding an acyl side chain. It may be necessary to introduce lysine residue into the sequence solely for the purpose of providing a convenient site at which to add an acyl side chain. Alternatively the acyl side chain may be added to the lysine residue in advance of the synthesis of the peptide, whereupon its incorporation at the relevant synthetic step will result directly in acylation. This methodology is advantageous if the peptide sequence contains more than one lysine residue as it avoids the necessity of using selective conditions that acylate only the particular lysine of interest. Preferably, the peptide derivatives have three, more preferably two, and most preferably one acyl side chain substituent. Examples of acyl (and other lipophilic substituents), approaches and specific synthetic methods of attaching such to peptides (with and without the use of spacers) are described in U.S. Patent No. 6,268,343; and U.S. Patent Number 6,458,924.

Pharmaceutically acceptable amides and carbonates of the compounds of formula (I) may comprise a C₁₋₆ alkyl-, C₅₋₁₀ aryl-, C₅₋₁₀ ar-C₁₋₆ alkyl-, or amino acid-ester or -amide, or – carbamate attached at an appropriate site, for example at an amino group.

Methods for lipidization of sulfhydryl-containing compounds with fatty acid derivatives are disclosed in U.S. Patent No. 5,936,092; U.S. Patent No. 6,093,692; and U.S. Patent No. 6,225,445. Fatty acid derivatives of a compound of the invention comprising a compound of the invention linked to fatty acid via a disulfide linkage may be used for delivery of a compound of the invention to neuronal cells and tissues. Lipidisation markedly increases the absorption of the compounds relative to the rate of absorption of the corresponding unlipidised compounds, as well as prolonging blood and tissue retention of the compounds. Moreover, the disulfide linkage in lipidised derivative is relatively labile in the cells and thus facilitates intracellular release of the molecule from the fatty acid moieties. Suitable lipid-containing moieties are hydrophobic substituents with 4 to 26 carbon atoms, preferably 5 to 19 carbon atoms. Suitable lipid groups include, but are not limited to, the following: palmityl (C₁₅H₃₁), oleyl (C₁₅H₂₉), stearyl (C₁₇H₃₅), cholate; and deoxycholate.

-15-

Cyclization methods include cyclization through the formation of a disulfide bridge and head-to-tail cyclization using a cyclization resin. Cyclized peptides may have enhanced stability, including increased resistance to enzymatic degradation, as a result of their conformational constraints. Cyclization may in particular be expedient where the
5 uncyclized peptide includes an N-terminal cysteine group. Suitable cyclized peptides include monomeric and dimeric head-to-tail cyclized structures. Cyclized peptides may include one or more additional residues, especially an additional cysteine incorporated for the purpose of formation of a disulfide bond or a side chain incorporated for the purpose of resin-based cyclization.

10 A compound of the invention may be a pegylated structure of formula (I). Pegylated compounds of the invention may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent No. 4,179,337).

15 Chemical moieties for derivitization of a compound of the invention may also be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. A polymer moiety for derivatisation of a compound of the invention may be of any molecular weight,
20 and may be branched or unbranched. For ease in handling and manufacturing, the preferred molecular weight of a polyethylene glycol for derivatisation of a compound of the invention is from about 1 kDa to about 100 kDa, the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight. Polymers of other molecular weights may be used, depending on
25 the desired therapeutic profile, for example the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog. For example, the polyethylene glycol may have an average molecular weight of about 200,
30 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500,

-16-

19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000, 50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, 95,000, or 100,000 kDa.

Salts and solvates of compounds of the invention that are suitable for use in a medicament
5 are those wherein a counterion or associated solvent is pharmaceutically acceptable.
However, salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of the compounds of formula (I) and their pharmaceutically acceptable salts or solvates.

10

Suitable salts according to the invention include those formed with organic or inorganic acids or bases. Pharmaceutically acceptable acid addition salts include those formed with hydrochloric, hydrobromic, sulphuric, nitric, citric, tartaric, acetic, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, succinic, perchloric, fumaric, maleic, glycollic, lactic,
15 salicylic, oxaloacetic, methanesulfonic, ethanesulfonic, p-toluenesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic, benzenesulfonic, and isethionic acids. Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutical acceptable salts. Pharmaceutically acceptable salts with bases include ammonium salts,
20 alkali metal salts, for example potassium and sodium salts, alkaline earth metal salts, for example calcium and magnesium salts, and salts with organic bases, for example dicyclohexylamine and N-methyl-D-glucamine.

Those skilled in the art of organic chemistry will appreciate that many organic compounds
25 can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. Such complexes are known as "solvates". For example, a complex with water is known as a "hydrate". The present invention provides solvates of compounds of the invention.

30 **Conditions:**

The invention provides a pharmaceutical composition comprising a compound of formula (I). The invention further provides the compound of formula (I) for use as a medicament.

-17-

The invention also provides a compound of formula (I) for use in the treatment of obesity or diabetes. The invention further provides a compound of formula (I) for use in reduction of appetite in a subject, for use in reduction of food intake in a subject, or for use in reduction of calorie intake in a subject.

5

The invention further provides the use of a compound of formula (I) for the manufacture of a medicament for the treatment of obesity or diabetes. The invention also provides the use of a compound of formula (I) for the manufacture of a medicament for reducing appetite in a subject, reducing food intake in a subject, or reducing calorie intake in a subject.

10

The invention further provides a method of treating obesity or diabetes in a subject in need thereof comprising administering to the subject an effective amount of a compound of formula (I). The invention also provides a method of reducing appetite in a subject, reducing food intake in a subject, or reducing calorie intake in a subject, comprising administering to the subject an effective amount of a compound of formula (I).

15

The subject to whom the compound is administered may be overweight, for example, obese. Alternatively, or in addition, the subject may be diabetic, for example having insulin resistance or glucose intolerance, or both. The subject may have diabetes mellitus, for example, the subject may have Type II diabetes. The subject may be overweight, for example, obese and have diabetes mellitus, for example, Type II diabetes.

20

In addition, or alternatively, the subject may have, or may be at risk of having, a disorder in which obesity or being overweight is a risk factor. Such disorders include, but are not limited to, cardiovascular disease, for example hypertension, atherosclerosis, congestive heart failure, and dyslipidemia; stroke; gallbladder disease; osteoarthritis; sleep apnea; reproductive disorders for example, polycystic ovarian syndrome; cancers, for example breast, prostate, colon, endometrial, kidney, and esophagus cancer; varicose veins; acanthosis nigricans; eczema; exercise intolerance; insulin resistance; hypertension hypercholesterolemia; cholelithiasis; osteoarthritis; orthopedic injury; insulin resistance, for example, type 2 diabetes and syndrome X; and thromboembolic disease (see Kopelman, *Nature* 404:635-43; Rissanen et al., *British Med. J.* 301, 835, 1990).

25

30

-18-

Other disorders associated with obesity include depression, anxiety, panic attacks, migraine headaches, PMS, chronic pain states, fibromyalgia, insomnia, impulsivity, obsessive compulsive disorder, and myoclonus. Furthermore, obesity is a recognized risk factor for increased incidence of complications of general anesthesia. (See e.g.,

- 5 Kopelman, *Nature* 404:635-43, 2000). In general, obesity reduces life span and carries a serious risk of co-morbidities such as those listed above.

- Other diseases or disorders associated with obesity are birth defects, maternal obesity being associated with increased incidence of neural tube defects, carpal tunnel syndrome
10 (CTS); chronic venous insufficiency (CVI); daytime sleepiness; deep vein thrombosis (DVT); end stage renal disease (ESRD); gout; heat disorders; impaired immune response; impaired respiratory function; infertility; liver disease; lower back pain; obstetric and gynecologic complications; pancreatitis; as well as abdominal hernias; acanthosis nigricans; endocrine abnormalities; chronic hypoxia and hypercapnia; dermatological
15 effects; elephantitis; gastroesophageal reflux; heel spurs; lower extremity edema; mammegaly which causes considerable problems such as bra strap pain, skin damage, cervical pain, chronic odors and infections in the skin folds under the breasts, etc.; large anterior abdominal wall masses, for example abdominal panniculitis with frequent panniculitis, impeding walking, causing frequent infections, odors, clothing difficulties,
20 low back pain; musculoskeletal disease; pseudo tumor cerebri (or benign intracranial hypertension), and sliding hiatal hernia.

- The present invention further provides a method for increasing energy expenditure in a subject. The method includes, for example, peripherally administering a therapeutically
25 effective amount of a compound of the invention to the subject, thereby altering energy expenditure. Energy is burned in all physiological processes. The body can alter the rate of energy expenditure directly, by modulating the efficiency of those processes, or changing the number and nature of processes that are occurring. For example, during digestion the body expends energy moving food through the bowel, and digesting food,
30 and within cells, the efficiency of cellular metabolism can be altered to produce more or less heat.

-19-

In one aspect, the method of the invention involves manipulation of the arcuate circuitry, that alter food intake coordinately and reciprocally alter energy expenditure. Energy expenditure is a result of cellular metabolism, protein synthesis, metabolic rate, and calorie utilization. Thus, in this aspect of the invention, administration of a compound of formula

5 (I) results in increased energy expenditure, and decreased efficiency of calorie utilization

The invention also provides a method for improving a lipid profile in a subject. The invention also provides a method for alleviating a condition or disorder that can be alleviated by reducing nutrient availability.

10

Appetite can be measured by any means known to one of skill in the art. For example, decreased appetite can be assessed by a psychological assessment. For example, administration of a compound of the invention results in a change in perceived hunger, satiety, and/or fullness. Hunger can be assessed by any means known to one of skill in the

15 art. For example, hunger is assessed using psychological assays, such as by an assessment of hunger feelings and sensory perception using a questionnaire, such as, but not limited to, a Visual Analog Score (VAS) questionnaire. In one specific, non-limiting example, hunger is assessed by answering questions relating to desire for food, drink, prospective food consumption, nausea, and perceptions relating to smell or taste.

20 A compound of the invention may be used for weight control and treatment, for example reduction or prevention of obesity, in particular any one or more of the following: preventing and reducing weight gain; inducing and promoting weight loss; and reducing obesity as measured by the Body Mass Index. A compound of the invention may be used

25 in the control of any one or more of appetite, satiety and hunger, in particular any one or more of the following: reducing, suppressing and inhibiting appetite; inducing, increasing, enhancing and promoting satiety and sensations of satiety; and reducing, inhibiting and suppressing hunger and sensations of hunger. A compound of the invention may be used in maintaining any one or more of a desired body weight, a desired Body Mass Index, a

30 desired appearance and good health.

-20-

A subject may be a subject who desires weight loss, for example female and male subjects who desire a change in their appearance. A subject may desire decreased feelings of hunger, for example the subject may be a person involved in a lengthy task that requires a high level of concentration, for example soldiers on active duty, air traffic controllers, or truck drivers on long distance routes, etc..

The present invention may also be used in treating, prevention, ameliorating or alleviating conditions or disorders caused by, complicated by, or aggravated by a relatively high nutrient availability. The term "condition or disorder which can be alleviated by reducing caloric (or nutrient) availability" is used herein to denote any condition or disorder in a subject that is either caused by, complicated by, or aggravated by a relatively high nutrient availability, or that can be alleviated by reducing nutrient availability, for example by decreasing food intake. Subjects who are insulin resistant, glucose intolerant; or have any form of diabetes mellitus, for example, type 1, 2 or gestational diabetes, can also benefit from methods in accordance with the present invention.

Conditions or disorders associated with increased caloric intake include, but are not limited to, insulin resistance, glucose intolerance, obesity, diabetes, including type 2 diabetes, eating disorders, insulin-resistance syndromes, and Alzheimer's disease.

According to the present invention, a compound of formula (I) is preferably used in the treatment of a human. However, while the compounds of the invention will typically be used to treat human subjects they may also be used to treat similar or identical conditions in other vertebrates for example other primates; farm animals for example swine, cattle and poultry; sport animals for example horses; companion animals for example dogs and cats.

Compositions

While it is possible for the active ingredient to be administered alone, it is preferable for it to be present in a pharmaceutical formulation or composition. Accordingly, the invention provides a pharmaceutical formulation comprising a compound of formula (I), or a variant or derivative thereof, or a salt or solvate thereof, as defined above and a pharmaceutically

-21-

acceptable excipient. Pharmaceutical compositions of the invention may take the form of a pharmaceutical formulation as described below.

The pharmaceutical formulations according to the invention include those suitable for oral,
5 parenteral (including subcutaneous, intradermal, intramuscular, intravenous, and
intraarticular), inhalation (including fine particle dusts or mists which may be generated by
means of various types of metered dose pressurized aerosols, nebulizers or insufflators),
rectal and topical (including dermal, transdermal, transmucosal, buccal, sublingual, and
intraocular) administration, although the most suitable route may depend upon, for
10 example, the condition and disorder of the recipient.

The formulations may conveniently be presented in unit dosage form and may be prepared
by any of the methods well known in the art of pharmacy. All methods include the step of
bringing the active ingredient into association with the carrier which constitutes one or
15 more accessory ingredients. In general the formulations are prepared by uniformly and
intimately bringing into association the active ingredient with liquid carriers or finely
divided solid carriers or both and then, if necessary, shaping the product into the desired
formulation.

20 Formulations of the present invention suitable for oral administration may be presented as
discrete units such as capsules, cachets or tablets each containing a predetermined amount
of the active ingredient; as a powder or granules; as a solution or a suspension in an
aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-
oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or
25 paste. Various pharmaceutically acceptable carriers and their formulation are described in
standard formulation treatises, e.g., *Remington's Pharmaceutical Sciences* by E. W.
Martin. See also Wang, Y. J. and Hanson, M. A., *Journal of Parenteral Science and
Technology*, Technical Report No. 10, Supp. 42:2S, 1988.

30 A tablet may be made by compression or moulding, optionally with one or more accessory
ingredients. Compressed tablets may be prepared by compressing in a suitable machine
the active ingredient in a free-flowing form such as a powder or granules, optionally mixed

-22-

with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent.

Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. The present compounds can, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release can be achieved by the use of suitable pharmaceutical compositions comprising the present compounds, or, particularly in the case of extended release, by the use of devices such as subcutaneous implants or osmotic pumps. The present compounds can also be administered liposomally.

Exemplary compositions for oral administration include suspensions which can contain, for example, microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweeteners or flavoring agents such as those known in the art; and immediate release tablets which can contain, for example, microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and/or lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants such as those known in the art. The compounds of formula (I) can also be delivered through the oral cavity by sublingual and/or buccal administration. Molded tablets, compressed tablets or freeze-dried tablets are exemplary forms which may be used. Exemplary compositions include those formulating the present compound(s) with fast dissolving diluents such as mannitol, lactose, sucrose and/or cyclodextrins. Also included in such formulations may be high molecular weight excipients such as celluloses (avicel) or polyethylene glycols (PEG). Such formulations can also include an excipient to aid mucosal adhesion such as hydroxy propyl cellulose (HPC), hydroxy propyl methyl cellulose (HPMC), sodium carboxy methyl cellulose (SCMC), maleic anhydride copolymer (e.g., Gantrez), and agents to control release such as polyacrylic copolymer (e.g. Carbopol 934). Lubricants, glidants, flavors, coloring agents and stabilizers may also be added for ease of fabrication and use.

Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes

-23-

which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example saline or water-for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described. Exemplary compositions for parenteral administration include injectable solutions or suspensions which can contain, for example, suitable non-toxic, parenterally acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution, an isotonic sodium chloride solution, or other suitable dispersing or wetting and suspending agents, including synthetic mono- or diglycerides, and fatty acids, including oleic acid, or Cremaphor. An aqueous carrier may be, for example, an isotonic buffer solution at a pH of from about 3.0 to about 8.0, preferably at a pH of from about 3.5 to about 7.4, for example from 3.5 to 6.0, for example from 3.5 to about 5.0. Useful buffers include sodium citrate-citric acid and sodium phosphate-phosphoric acid, and sodium acetate/acetic acid buffers. The composition preferably does not include oxidizing agents and other compounds that are known to be deleterious to PYY and PYY agonists. Excipients that can be included are, for instance, other proteins, such as human serum albumin or plasma preparations. If desired, the pharmaceutical composition may also contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.

Exemplary compositions for nasal aerosol or inhalation administration include solutions in saline, which can contain, for example, benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, and/or other solubilizing or dispersing agents such as those known in the art. Conveniently in a compositions for nasal aerosol or inhalation administration the compound of the invention is delivered in the form of an aerosol spray presentation from a pressurized pack or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoro-methane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a

-24-

pressurized aerosol the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator can be formulated to contain a powder mix of the compound and a suitable powder base, for example lactose or starch. In one specific, non-limiting example, a compound of the invention is administered as an aerosol from a metered dose valve, through an aerosol adapter also known as an actuator. Optionally, a stabilizer is also included, and/or porous particles for deep lung delivery are included (e.g., see U.S. Patent No. 6,447,743).

Formulations for rectal administration may be presented as a retention enema or a suppository with the usual carriers such as cocoa butter, synthetic glyceride esters or polyethylene glycol. Such carriers are typically solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.

Formulations for topical administration in the mouth, for example buccally or sublingually, include lozenges comprising the active ingredient in a flavoured basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerine or sucrose and acacia. Exemplary compositions for topical administration include a topical carrier such as Plastibase (mineral oil gelled with polyethylene).

Preferred unit dosage formulations are those containing an effective dose, as hereinbefore recited, or an appropriate fraction thereof, of the active ingredient.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.

The compounds of the invention are also suitably administered as sustained-release systems. Suitable examples of sustained-release systems of the invention include suitable polymeric materials, for example semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules; suitable hydrophobic materials, for example as an

-25-

emulsion in an acceptable oil; or ion exchange resins; and sparingly soluble derivatives of the compound of the invention, for example, a sparingly soluble salt. Sustained-release systems may be administered orally; rectally; parenterally; intracisternally; intravaginally; intraperitoneally; topically, for example as a powder, ointment, gel, drop or transdermal patch; buccally; or as an oral or nasal spray.

Preparations for administration can be suitably formulated to give controlled release of compounds of the invention. For example, the pharmaceutical compositions may be in the form of particles comprising one or more of biodegradable polymers, polysaccharide jellifying and/or bioadhesive polymers, amphiphilic polymers, agents capable of modifying the interface properties of the particles of the compound of formula (I). These compositions exhibit certain biocompatibility features which allow a controlled release of the active substance. See U.S. Patent No. 5,700,486.

A compound of the invention may be delivered by way of a pump (see Langer, *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201, 1987; Buchwald et al., *Surgery* 88:507, 1980; Saudek et al., *N. Engl. J. Med.* 321:574, 1989) or by a continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The key factor in selecting an appropriate dose is the result obtained, as measured by decreases in total body weight or ratio of fat to lean mass, or by other criteria for measuring control or prevention of obesity or prevention of obesity-related conditions, as are deemed appropriate by the practitioner. Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533, 1990). In another aspect of the disclosure, compounds of the invention are delivered by way of an implanted pump, described, for example, in U.S. Patent No. 6,436,091; U.S. Patent No. 5,939,380; U.S. Patent No. 5,993,414.

Implantable drug infusion devices are used to provide patients with a constant and long term dosage or infusion of a drug or any other therapeutic agent. Essentially such device may be categorized as either active or passive. A compound of the present invention may be formulated as a depot preparation. Such a long acting depot formulation can be administered by implantation, for example subcutaneously or intramuscularly; or by

-26-

intramuscular injection. Thus, for example, the compounds can be formulated with suitable polymeric or hydrophobic materials, for example as an emulsion in an acceptable oil; or ion exchange resins; or as a sparingly soluble derivatives, for example, as a sparingly soluble salt.

5

A therapeutically effective amount of a compound of the invention may be administered as a single pulse dose, as a bolus dose, or as pulse doses administered over time. Thus, in pulse doses, a bolus administration of a compound of the invention is provided, followed by a time period wherein no a compound of the invention is administered to the subject, followed by a second bolus administration. In specific, non-limiting examples, pulse doses of a compound of the invention are administered during the course of a day, during the course of a week, or during the course of a month.

In one embodiment, a therapeutically effective amount of a compound of the invention is administered with a therapeutically effective amount of another agent, for example an additional appetite suppressant, a food-intake-reducing, plasma glucose-lowering or plasma lipid-altering agent. Specific, non-limiting example of an additional appetite suppressant include amfepramone (diethylpropion), phentermine, mazindol and phenylpropanolamine, fenfluramine, dexfenfluramine, and fluoxetine. The compound of the invention can be administered simultaneously with the additional appetite suppressant, or it may be administered sequentially. Thus, in one embodiment, the compound of the invention is formulated and administered with an appetite suppressant as a single dose.

A compound of the invention may be administered whenever the effect, e.g., appetite suppression, decreased food intake, or decreased caloric intake, is desired, or slightly before to whenever the effect is desired, such as, but not limited to about 10 minutes, about 15 minutes, about 30 minutes, about 60 minutes, about 90 minutes, or about 120 minutes, before the time the effect is desired.

30 **Dosages**

The therapeutically effective amount of a compound of the invention will be dependent on the molecule utilized, the subject being treated, the severity and type of the affliction, and

-27-

the manner and route of administration. For example, a therapeutically effective amount of a compound of the invention may vary from about 0.01 µg per kilogram (kg) body weight to about 1 g per kg body weight, for example about 1 µg to about 5 mg per kg body weight, or about 5 µg to about 1 mg per kg body weight. A compound of the invention

5 may be administered to a subject at 0.5 to 135 picomole (pmol) per kg body weight, or about 72 pmol per kg body weight. In one specific, non-limiting example, a compound of the invention is administered in a dose of about 1 nmol or more, 2 nmol or more, or 5 nmol or more. In this example, the dose of the compound of the invention is generally not more than 100 nmol, for example, the dose is 90 nmols or less, 80 nmols or less, 70 nmols or

10 less, 60 nmols or less, 50 nmols or less, 40 nmols or less, 30 nmols or less, 20 nmols or less, 10 nmols. For example, a dosage range may comprise any combination of any of the specified lower dose limits with any of the specified upper dose limits. Thus, examples of non-limiting dose ranges of compounds of the invention are within the range of from 1 to 100 nmols, from 1 to 90 nmols, from 1 to 80 nmols.

15

In one specific, non-limiting example, from about 5 to about 50 nmol of a compound of the invention is administered, for example about 2 to about 20 nmol, for example about 10 nmol is administered as a subcutaneous injection. The exact dose is readily determined by one of skill in the art based on the potency of the specific compound utilized, the age,

20 weight, sex and physiological condition of the subject.

Suitable doses of compounds of the invention also include those that result in a reduction in calorie intake, food intake, or appetite, or increase in energy expenditure that is equivalent to the reduction in calorie intake, food intake, or appetite, or to increase the

25 energy expenditure, caused by the normal postprandial level of PYY3-36. Examples of doses include, but are not limited to doses that produce the effect demonstrated when the serum levels of PYY are from about 40 pM to about 60 pM, or from about 40 pM to about 45 pM, or about 43 pM.

30 The disclosure is illustrated by the following non-limiting Examples.

-28-

8. EXAMPLES

Materials and Methods:

Male C57BL/6 mice (20-30 g) were used for all mouse experiments. Male Wistar rats were used for the rat experiments. Mice or rats were individually housed in IVC cages. Animals were randomised by weight and fasted overnight for 16 hrs before intraperitoneal injection at 9am. Food intake was measured at 1, 2, 4, 6 and 24 hours post injection. All peptide solutions were prepared freshly the morning of the study and injected as 100 µl. All statistics are calculated using the student's paired t-test.

Peptide Synthesis

Peptide synthesis of allo_ILeu³ PYY(3-36) and D_allo_ILeu³ PYY(3-36) was carried out on a tryclic amide linker resin. The sequences were the human PYY sequences. Amino acids were attached using the Fmoc strategy. Each amino acid was added sequentially from the C- to the N-termini. Peptide couplings were mediated by the reagent TBTU. Peptide cleavage from the resin was achieved with trifluoroacetic acid in the presence of scavengers. Native PYY(3-36) is obtained as described previously (WO03/026591); de novo synthesis using tryclic amide resin and Fmoc chemistry is also possible.

Peptides were purified by reverse phase HPLC. Full quality control was performed on all purified peptides and peptides were shown to be greater than 95% pure by HPLC in two buffer systems. Amino acid analysis following acid hydrolysis confirmed the amino acid composition. MALDI-MS showed the expected molecular ion.

Results:

Example 1: Administration of 3 different PYY analogues to mice

Mice were injected with PYY(3-36) 100 µg/kg, allo_ILeu³ PYY(3-36) 100 µg/kg, D_allo_ILeu³ PYY(3-36) 100 µg/kg or saline (n=10/group) and food intake was measured at time intervals over 24 hours. The results are shown in Figure 1. In the Figure, significance versus saline is indicated by * = p<0.05, ** = p<0.01, *** = p<0.001 paired t-test. As well as a significantly decreased food intake compared with saline food intake the

-29-

PYY(3-36) analogue D_allo_ILeu³ PYY(3-36) injected animals also had significantly reduced cumulative food intake compared to the PYY(3-36) injected group at 0-1 hr ($p=0.0138$), 0-2 hr ($p=0.0063$), 0-4 hr ($p=0.0003$) and 0-6 hr ($p=0.0024$). The D_allo_ILeu³ PYY(3-36) injected animals almost showed a significant reduction in food intake over a 24 hr period compared to the PYY(3-36) 100 µg/kg group ($p=0.0554$). In contrast, allo_ILeu³ PYY(3-36) and D_ILeu³ PYY(3-36) showed essentially the same effect as PYY(3-36).

Example 2: Dose response experiment for D_allo_ILeu³ PYY(3-36) in mice

As there was a significantly enhanced response with the D_allo_ILeu³ PYY(3-36) analogue a dose response experiment was carried out in order to determine to what degree D_allo_ILeu³ PYY(3-36) was more effective than PYY(3-36) at decreasing food intake after peripheral injection in mice. 30 µg/kg or 100 µg/kg of PYY(3-36) or D_allo_ILeu³ PYY(3-36) was injected after an overnight fast and food intake was measured at time intervals over a period of 24 hours. The results for the 0 to 4 hr time period are shown in Figure 2A. The results for the 0 to 24 hr time period are shown in Figure 2B. In the Figures, significance versus saline is indicated by * = $p<0.05$, ** = $p<0.01$, *** = $p<0.001$ paired t-test. The results indicate that 30 µg/kg of D_allo_ILeu³ PYY(3-36) is at least as powerful at reducing food intake as a 100 µg/kg dose of PYY(3-36) suggesting a 3-fold superiority in efficacy.

Example 3: Dose response experiment for D_allo_ILeu³ PYY(3-36) in rats

A dose response experiment was carried out in order to determine to what degree D_allo_ILeu³ PYY(3-36) was more effective than PYY(3-36) at decreasing food intake after peripheral injection in rats. The experiment was identical to Example 2, except that Wistar rats were used instead of C57BL/6 mice. 30 µg/kg or 100 µg/kg of PYY(3-36) or D_allo_ILeu³ PYY(3-36) was injected after an overnight fast and food intake was measured at time intervals over a period of 24 hours. The results for the 0 to 4 hr time period are shown in Figure 3A. The results for the 0 to 24 hr time period are shown in Figure 3B. In the Figures, significance versus saline is indicated by * = $p<0.05$, ** = $p<0.01$, *** = $p<0.001$ paired t-test. The results indicate that 30 µg/kg of D_allo_ILeu³


-30-

PYY(3-36) is at least as powerful at reducing food intake as a 100 µg/kg dose of PYY(3-36) suggesting a 3-fold superiority in efficacy.

-31-

CLAIMS

1. A compound of formula (I):



(I)

a variant or derivative thereof;

or a salt or solvate thereof.

2. A compound as claimed in claim 1 wherein the PYY₄₋₃₆ is human PYY₄₋₃₆.

3. A compound as claimed in claim 1 or claim 2 in which the PYY₄₋₃₆ is a variant of a native PYY₄₋₃₆ with 1, 2, 3 or 4 modifications selected from deletions, insertions, inversions, repeats and substitutions.

4. A compound as claimed in any one of claims 1 to 3 in which the PYY₄₋₃₆ includes at least 30 amino acids of the native PYY₄₋₃₆ sequence.

5. A compound as claimed in any one of claims 1 to 4 which is a derivative that is modified by one or more processes selected from amidation, glycosylation, carbamylation, acylation, sulfation, phosphorylation, cyclization, lipidization and pegylation.

6. A compound as claimed in any one of claims 1 to 5 which is a derivative that is a fusion protein.

7. A compound as claimed in claim 6 that is produced by a recombinant method.

8. A compound as claimed in claim 6 that is produced by a synthetic method.

-32-

9. A compound as claimed in any one of claims 1 to 8 for use as a medicament.
10. A pharmaceutical composition comprising a compound as claimed in any one of
5 claims 1 to 9.
11. A compound as claimed in any one of claims 1 to 9 for use in the treatment of obesity or diabetes.
- 10 12. A compound as claimed in any one of claims 1 to 9 for use in the reduction of appetite in a subject, use in the reduction of food intake in a subject, or for use in the reduction of calorie intake in a subject.
13. A method of treating obesity or diabetes in a subject in need thereof comprising
15 administering to the subject a compound of any one of claims 1 to 9.
14. A method of reducing appetite in a subject, reducing food intake in a subject, or reducing calorie intake in a subject, comprising administering to the subject a compound of any one of claims 1 to 9.
20
15. The method of claim 13 or claim 14, wherein the subject is overweight.
16. The method of claim 13 or claim 14, wherein the subject is obese.
- 25 17. The method of claim 13 or claim 14, wherein the subject is diabetic.
18. The method of any one of claims 13 to 17, wherein the compound is administered peripherally.
- 30 19. The method of any one of claims 13 to 17 wherein the compound is administered subcutaneously, intravenously, intramuscularly, intranasally, transdermally or sublingually.

-33-

20. Use of a compound as claimed in any one of claims 1 to 9 for the manufacture of a medicament for the treatment of obesity or diabetes.

- 5 21. Use of a compound as claimed in any one of claims 1 to 9 for the manufacture of a medicament for the reduction of appetite in a subject, for the reduction of food intake in a subject, or for the reduction of calorie intake in a subject.

10

15

20

25

30

1/5




Figure 1

2/5




Figure 2A

3/5




Figure 2B

4/5




Figure 3A

5/5




Figure 3B

10763 WO Seq listing
SEQUENCE LISTING

<110> Imperial Innovations Limited

<120> Novel Compounds and Their Effects on Feeding Behaviour

<130> 10763 WO PAB/PMBC

<150> GB0504857.4

<151> 2005-03-09

<160> 10

<170> PatentIn version 3.1

<210> 1

<211> 36

<212> PRT

<213> Homo sapiens

<400> 1

Tyr Pro Ile Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu
1 5 10 15Leu Asn Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr
20 25 30Arg Gln Arg Tyr
35

<210> 2

<211> 33

<212> PRT

<213> Homo sapiens

<400> 2

Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu Leu Asn Arg
1 5 10 15Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr Arg Gln Arg
20 25 30

Tyr

<210> 3

<211> 36

<212> PRT

<213> Rattus sp.

<400> 3

Tyr Pro Ala Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu
1 5 10 15Leu Ser Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr
20 25 30Arg Gln Arg Tyr
35

<210> 4

10763 WO Seq listing

<211> 36
 <212> PRT
 <213> Sus sp.

<400> 4

Tyr Pro Ala Lys Pro Glu Ala Pro Gly Glu Asp Ala Ser Pro Glu Glu
 1 5 10 15
 Leu Ser Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr
 20 25 30
 Arg Gln Arg Tyr
 35

<210> 5
 <211> 36
 <212> PRT
 <213> Cavia porcellus

<400> 5

Tyr Pro Ser Lys Pro Glu Ala Pro Gly Ser Asp Ala Ser Pro Glu Glu
 1 5 10 15
 Leu Ala Arg Tyr Tyr Ala Ser Leu Arg His Tyr Leu Asn Leu Val Thr
 20 25 30
 Arg Gln Arg Tyr
 35

<210> 6
 <211> 36
 <212> PRT
 <213> Rana sp.

<400> 6

Tyr Pro Pro Lys Pro Glu Asn Pro Gly Glu Asp Ala Ser Pro Glu Glu
 1 5 10 15
 Met Thr Lys Tyr Leu Thr Ala Leu Arg His Tyr Ile Asn Leu Val Thr
 20 25 30
 Arg Gln Arg Tyr
 35

<210> 7
 <211> 36
 <212> PRT
 <213> Raja sp.

<400> 7

Tyr Pro Pro Lys Pro Glu Asn Pro Gly Asp Asp Ala Ala Pro Glu Glu
 1 5 10 15
 Leu Ala Lys Tyr Tyr Ser Ala Leu Arg His Tyr Ile Asn Leu Ile Thr
 20 25 30
 Arg Gln Arg Tyr
 35

<210> 8

10763 WO Seq listing

<211> 36
<212> PRT
<213> Dogfish sp.

<400> 8

Tyr Pro Pro Lys Pro Glu Asn Pro Gly Glu Asp Ala Pro Pro Glu Glu
1 5 10 15
Leu Ala Lys Tyr Tyr Ser Ala Leu Arg His Tyr Ile Asn Leu Ile Thr
20 25 30
Arg Gln Arg Tyr
35

<210> 9
<211> 36
<212> PRT
<213> Lampetra sp.

<400> 9

Phe Pro Pro Lys Pro Asp Asn Pro Gly Asp Asn Ala Ser Pro Glu Gln
1 5 10 15
Met Ala Arg Tyr Lys Ala Ala Val Arg His Tyr Ile Asn Leu Ile Thr
20 25 30
Arg Gln Arg Tyr
35

<210> 10
<211> 36
<212> PRT
<213> Petromyzontidae gen. sp.

<400> 10

Met Pro Pro Lys Pro Asp Asn Pro Ser Pro Asp Ala Ser Pro Glu Glu
1 5 10 15
Leu Ser Lys Tyr Met Leu Ala Val Arg Asn Tyr Ile Asn Leu Ile Thr
20 25 30
Arg Gln Arg Tyr
35

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2006/000822

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K14/575 A61K38/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data, PAJ, Sequence Search, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2004/066966 A (SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.) 12 August 2004 (2004-08-12) abstract page 6, paragraph 022 -----	1-21
A	US 5 328 899 A (BOUBLIK ET AL) 12 July 1994 (1994-07-12) abstract column 2, line 50 - line 57 column 10; examples 23,24 column 11; example 25 column 12; examples 39-42 -----	1-21
A	US 5 604 203 A (BALASUBRAMANIAM ET AL) 18 February 1997 (1997-02-18) the whole document ----- -/-	1-21

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

10 July 2006

Date of mailing of the international search report

28/07/2006

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Grötzinger, T

INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2006/000822

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>EBERLEIN G A ET AL: "A NEW MOLECULAR FORM OF PYY: STRUCTURAL CHARACTERIZATION OF HUMAN PYY(3-36) AND PYY(1-36)" PEPTIDES, ELSEVIER, AMSTERDAM, US, vol. 10, no. 4, 1989, pages 797-803, XP001079678 ISSN: 0196-9781 the whole document</p>	1-21
A	<p>US 2003/219879 A1 (ROZZELL J. DAVID ET AL) 27 November 2003 (2003-11-27) the whole document</p>	1-21

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2006/000822

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13-19
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 13 to 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: -
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claims 13 to 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box II.2

Claims Nos.: -

Present claim 1 relates to a modified PYY peptide but also to variants and derivatives of. However, the application does not provide support and disclosure in the sense of Article 6 and 5 PCT for any such variant or derivative and there is no common general knowledge of this kind available to the person skilled in the art. This non-compliance with the substantive provisions is to such an extent, that the search was performed taking into consideration the non-compliance in determining the extent of the search of the claim (PCT Guidelines 9.19 and 9.20).

The search of claim 1 was consequently restricted to the specifically disclosed variants and derivatives mentioned in claim 3 and claim 5, respectively.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2006/000822

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2004066966	A	12-08-2004	EP 1583549 A2	12-10-2005
US 5328899	A	12-07-1994	NONE	
US 5604203	A	18-02-1997	AU 685803 B2	29-01-1998
			AU 6621494 A	24-10-1994
			CA 2157766 A1	13-10-1994
			CN 1124927 A	19-06-1996
			EP 0692971 A1	24-01-1996
			FI 954559 A	26-09-1995
			HU 73494 A2	28-08-1996
			JP 8510205 T	29-10-1996
			NZ 265452 A	22-09-1997
			PL 310897 A1	08-01-1996
			SG 52542 A1	28-09-1998
			SK 121895 A3	01-10-1996
			WO 9422467 A1	13-10-1994
US 2003219879	A1	27-11-2003	NONE	